Current Clinical Trials

Agendia’s extensive clinical trials and research collaborations have produced numerous retrospective and prospective validation studies over the past decade, which have enabled the successful commercialization of genomic microarray assays, such as the FDA-cleared 70-gene MammaPrint profile. Recently published studies further support the prognostic and predictive clinical utility of MammaPrint for early stage breast cancer patients, and large, multi-institutional clinical trials, such as MINDACT and ISPY-2, can be expected to expand the assay’s clinical importance and indications for use. Recently, the five year prospective results of the RASTER study were published indicating that chemotherapy may be safely withheld in Low Risk breast cancer patients.  Published studies continue to support the strong prognostic and predictive clinical utility of Agendia’s genomic assays and ongoing large, multi-site clinical trials seek to expand clinical indications for use.